Immuneering Corporation (NASDAQ:IMRX) Receives $17.57 Consensus PT from Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $17.5714.

Several brokerages have recently commented on IMRX. Cantor Fitzgerald assumed coverage on shares of Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a report on Wednesday, June 24th. Needham & Company LLC upped their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th.

Hedge Funds Weigh In On Immuneering

Several large investors have recently added to or reduced their stakes in the company. Focus Financial Network Inc. acquired a new position in Immuneering in the second quarter worth $62,000. PVG Asset Management Corp acquired a new stake in shares of Immuneering during the first quarter worth $773,000. Weiss Asset Management LP acquired a new stake in shares of Immuneering during the first quarter worth $464,000. Cetera Investment Advisers bought a new position in shares of Immuneering in the 1st quarter worth about $67,000. Finally, Levin Capital Strategies L.P. bought a new position in shares of Immuneering in the 1st quarter worth about $53,000. 67.65% of the stock is currently owned by institutional investors.

Immuneering Price Performance

IMRX opened at $4.24 on Friday. Immuneering has a 12-month low of $2.90 and a 12-month high of $10.08. The stock has a market capitalization of $274.33 million, a PE ratio of -3.62 and a beta of 0.41. The firm’s fifty day moving average price is $4.73 and its 200 day moving average price is $4.99.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.09. On average, equities research analysts forecast that Immuneering will post -1.09 earnings per share for the current fiscal year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.